An expansion cohort study for NG-350A to demonstrate clinical proof-of-concept in patient populations with a single type of epithelial-derived solid tumor
Latest Information Update: 11 Jan 2023
At a glance
- Drugs NG 350A (Primary)
- Indications Carcinoma
- Focus Proof of concept; Therapeutic Use
- 11 Jan 2023 New trial record
- 05 Jan 2023 According to an Akamis Bio media releasre, this trial is expected to begin in early 2024.